protocolSection identificationModule nctId: NCT06282146, orgStudyIdInfo id: 2024P000252, briefTitle: Testing a Transdiagnostic TMS Treatment Target, acronym: T5, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-04-01, completionDateStruct date: 2026-04-01, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Brigham and Women's Hospital, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to test a new brain stimulation treatment target for individuals with depression plus at least one additional psychiatric disorder. The main question is to understand the safety profile of a non-invasive form of brain stimulation called accelerated intermittent theta burst stimulation when it is targeting the posterior parietal cortex. Additional questions focus on whether this stimulation improves symptoms of depression and other psychiatric disorders as well as whether this stimulation changes brain function., conditionsModule conditions: Major Depressive Disorder, conditions: Depression, conditions: Psychiatric Disorder, conditions: Mood Disorders, conditions: Mental Disorder, conditions: Anxiety Disorders, conditions: OCD, conditions: PTSD, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: transcranial magnetic stimulation, outcomesModule primaryOutcomes measure: Tolerability as measured by incidence of side effects on an accelerated TMS sensations and adverse events questionnaire, primaryOutcomes measure: Feasibility as measured by number of the 50 treatments completed, secondaryOutcomes measure: Montgomery-Åsberg Depression Rating Scale (MADRS), secondaryOutcomes measure: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision, Level 1 Self-Rated Cross-Cutting Symptom Measure (DSM-5-XC), secondaryOutcomes measure: World Health Organization Disability Assessment Schedule II (WHODAS 2.0), otherOutcomes measure: Beck Depression Inventory (BDI), otherOutcomes measure: Beck Anxiety Inventory (BAI), otherOutcomes measure: Adult Attention Deficit/Hyperactivity Disorder Self-Report Scale (AARS), otherOutcomes measure: Clinical Global Impression Scale (CGI), otherOutcomes measure: Illness Intrusiveness Rating Scale (IIRS), otherOutcomes measure: Perceived Stress Scale (PSS), otherOutcomes measure: Positive and Negative Symptom Scale (PANSS), otherOutcomes measure: Post Traumatic Stress Disorder Checklist for DSM-5 (PCL-5), otherOutcomes measure: Social Readjustment Rating Scale (SRRS), otherOutcomes measure: Yale Brown Obsessive-Compulsive Scale (Y-BOCS), otherOutcomes measure: Temperament and Character Inventory, Revised 140-item, otherOutcomes measure: Emotional Conflict Resolution Test, otherOutcomes measure: Learning, Multi-Source Interference Task (MSIT), otherOutcomes measure: Penn Emotion Recognition Task (ER-40), otherOutcomes measure: Death Suicide IAT, otherOutcomes measure: Young Mania Rating Scale (YMRS), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False